Download an up-to-date list of Australia's top 300 companies. Constituent data includes GICS Sectors, market cap and index weighting.
The S&P/ASX 300 Ex-A-REIT (Sector) seeks to measure the performance of the S&P/ASX 300, excluding equity and mortgage REITs. Franking credit versions of the index are also available.
“A trend that we’ve observed in the past year is that we’re seeing many more active ETFs coming to market, offering investors more tailored investment portfolios. “Looking ahead, if I had to sum up in a single word of what’s to come for the Australian ETF market, it would be ‘...
Market cap 683.80m AUD EPS (TTM) 0.9625 AUD Annual div (ADY) 0.7857 AUD Annual div yield (ADY) 5.22% Div ex-date Dec 24 2024 Div pay-date Jan 24 2025 Data delayed at least 20 minutes, as of Jan 24 2025 05:10 GMT. Events & Activity SGLLV:ASX price moved over +1.41% to 10.80...
Download Gabelli Small Cap Growth Fund;A stock data: historical GCASX stock prices from MarketWatch.
Complete list of Exchange Traded Funds (ETFs) trading on the ASX. Download (CSV) with Market Caps. Explanation of how they work. Pros & Cons.
CodeCompanySectorMarket CapWeight(%) 14D 1414 Degrees Ltd Industrials 21,133,400 0.001 1ST 1ST Group Ltd Health Care 12,738,500 0.001 3PL 3P Learning Ltd Consumer Discretionary 104,613,000 0.005 4DS 4DS Memory Ltd Information Technology 58,091,300 0.003 5GN 5G Networks Ltd 82,746,600 0.00...
ASX:CBA Market CapASX:CBA has a market cap or net worth of 243.44 billion as of March 21, 2025. Its market cap has increased by 23.16% in one year.Market Cap 243.44B Enterprise Value n/a Revenue 26.73B Ranking n/a PE Ratio 25.00 Stock Price 145.60...
% Price Change by Sector ETF componentsSPDR S&P/ASX 200 - AUD © Marketscreener.com Detailed heatmap Quotes and Performance 1 week-1.49% 1 month-2.70% 3 months-3.22% 6 months+1.25% Current year+0.16% More quotes My WatchlistMost popular (10)My previous session (0) ...
截至3月底,增发后公司最新股本(Shares Issued)为179,408,700 股,按照一季度收盘价0.099澳元计,对应市值(Market Cap) 17,761,461澳元 。 相关募集资金将用于相关临床前研究和NYR-BI03的I期人体临床试验,后者NYR-BI03是脑损伤计划的主要候选药物。 财务方面,截至去年年底,公司现金头寸4,644,530澳元,各项负债约484...